

## ORIGINAL ARTICLE

# Whole-exome sequencing and genome-wide association studies identify novel sarcopenia risk genes in Han Chinese

Shu Ran<sup>1</sup>  | Xiao He<sup>1</sup>  | Zi-Xuan Jiang<sup>1</sup>  | Yu Liu<sup>1</sup>  | Yu-Xue Zhang<sup>1</sup>  |  
Lei Zhang<sup>2,3</sup> | Gui-Shan Gu<sup>5</sup> | Yufang Pei<sup>2</sup> | Bao-Lin Liu<sup>1</sup> | Qing Tian<sup>6</sup> |  
Yong-Hong Zhang<sup>3,4</sup> | Jing-Yu Wang<sup>5</sup>  | Hong-Wen Deng<sup>6</sup> 

<sup>1</sup>School of Medical Instruments and Food Engineering, University of Shanghai for Science and Technology, Shanghai, PR China

<sup>2</sup>Center for Genetic Epidemiology and Genomics, School of Public Health, Soochow University, Jiangsu, PR China

<sup>3</sup>Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Jiangsu, PR China

<sup>4</sup>Department of Epidemiology and Statistics, School of Public Health, Soochow University, Jiangsu, PR China

<sup>5</sup>Ji Lin University, First Hospital, Changchun, PR China

<sup>6</sup>Department of Biostatistics, Tulane University, New Orleans, Louisiana, USA

## Correspondence

Hong-Wen Deng, Department of Biostatistics, Tulane University, New Orleans, Louisiana, USA.  
Email: hdeng2@tulane.edu

Jing-Yu Wang, Ji Lin University, First Hospital, Changchun, PR China.  
Email: wangran294@sohu.com

## Funding information

The study was partially supported by startup fund from University of Shanghai for Science and Technology and Shanghai Leading Academic Discipline Project (S30501). The investigators of this work were partially supported by grants from NIH (R01AG026564, RC2DE020756, R01AR057049, R01AR050496, and R03TW008221), a SCOR (Specialized Center of Research) grant (P50AR055081) supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the Office of Research on Women's Health (ORWH), the Edward G. Schlieder Endowment and the Franklin D. Dickson/Missouri Endowment, the National Natural Science Foundation of China (31301092 to Y.L., 31571291 to L.Z., 31501026 to Y.F.P.), and the Natural Science Foundation of Jiangsu Province (BK20150323 to Y.F.P.).

## Abstract

Sarcopenia is a complex polygenic disease, and its molecular mechanism is still unclear. Whole lean body mass (WLBM) is a heritable trait predicting sarcopenia. To identify genomic loci underlying, we performed a whole-exome sequencing (WES) of WLBM variation with high sequencing depth (more than 40\*) in 101 Chinese subjects. We then replicated in the major findings in the large-scale UK Biobank (UKB) cohort ( $N = 217,822$ ) for WLBM. The results of four single-nucleotide polymorphisms (SNPs) were significant both in the discovery stage and replication stage: SNP rs740681 (discovery  $p = 1.66 \times 10^{-6}$ , replication  $p = .05$ ), rs2272303 (discovery  $p = 3.20 \times 10^{-4}$ , replication  $p = 3.10 \times 10^{-4}$ ), rs11170413 (discovery  $p = 3.99 \times 10^{-4}$ , replication  $p = 2.90 \times 10^{-4}$ ), and rs2272302 (discovery  $p = 9.13 \times 10^{-4}$ , replication  $p = 3.10 \times 10^{-4}$ ). We combined  $p$  values of the significant SNPs. Functional annotations highlighted two candidate genes, including *FZRI* and *SOAT2*, that may exert pleiotropic effects to the development of body mass. Our findings provide useful insights that further enhance our understanding of genetic interplay in sarcopenia.

## KEYWORDS

Sarcopenia, single-nucleotide polymorphism (SNP), whole lean body mass (WLBM), whole-exome sequencing (WES)

Shu Ran and Xiao He have contributed equally to this work.

On behalf of all authors, the corresponding author states that there is no conflict of interest.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2020 The Authors. *Molecular Genetics & Genomic Medicine* published by Wiley Periodicals, LLC.

## 1 | INTRODUCTION

Sarcopenia was defined as age-related loss of skeletal muscle mass and function, which was associated with a range of other diseases and health problems such as osteoporosis, obesity, and increased mortality (Brzezczynska et al., 2017; Cederholm & Morley, 2015; Chen et al., 2014; Fielding et al., 2011; Hayashi, Abe, Fujita, Okai, & Ohira, 2018; Joglekar, Nau, & Mezhir, 2015; Monaco, Castiglioni, Monaco, & Tappero, 2017; Valter, Andrea, Massimiliano, & Marco, 2014); 13%–24% of the elderly white people under 70 years old have sarcopenia, and prevalence is high as 50% or more among those aged 80 years old or older (Baumgartner et al., 1998). The decline in the contractility of lean mass also leads to a decrease in the load on bones, which makes the bones in a state of disuse for a long time, and is easy to induce osteoporosis (Buckwalter, 1995). The diagnosis of sarcopenia is based on an assessment of skeletal muscle mass and/or muscle strength, as well as muscle functions (Zembroń-Łacny, Dziubek, Rogowski, Skorupka, & Dąbrowska, 2014). Skeletal muscle is under strong genetic control, with heritability estimates of 30%–85% for muscle strength and 50%–80% for muscle mass (Arden & Spector, 2010; Thomis et al., 2004). Whole lean body mass (WLBM) is composed of skeletal muscle (60%), viscera, and some other connective tissues (Vandewoude, Alish, Sauer, & Hegazi, 2012; Wolfe, 2006), with heritability over 50% (Hsu et al., 2012), which is a heritable trait predicting sarcopenia. WLBM can be measured accurately by dual-energy X-ray absorptiometry (DXA). Compared to other measurements, DXA is a simple, easy-to-use, approachable method with a low dose of radiation and a high degree of precision and accuracy, especially in determining the composition of the body at all local and random sites.

Bone and muscle have persistent paracrine crosstalk throughout life, and they both respond to paracrine and endocrine stimuli in common. A decrease in muscle contraction leads to a decrease in bone load, which leads to a loss of skeletal integrity. Osteoblasts and muscle cells share a common mesenchymal precursor during embryonic development (Hsu et al., 2012). Based on the biological information of the interaction between bone mineral density (BMD) and LM, it is predicted that there may be shared genetic background underlying both traits, that is, pleiotropic genes. Besides, sarcopenia and obesity interact and influence each other on physiological and behavioral levels (Roubenoff, 2000). According to the inconsistent definitions of sarcopenic obesity and studies with different populations, the prevalence of sarcopenic obesity was estimated to be 4%–12% (Cauley, (2015). Both sarcopenia and obesity have high genetic susceptibility, so there may be pleiotropic loci to influence the risks of both diseases.

In the present study, aiming to achieve a better understanding of the genetic etiology of sarcopenia, we conducted a genome-wide association study of WLBM using the 101 Chinese

subjects as discovery sample and a follow-up replication study in the UK Biobank (UKB) sample. In addition, we conducted a series of bioinformatic analysis including cis-eQTL analysis, to explore the functional relevance of the identified genes including *FZRI* (OMIM 603,619) and *SOAT2* (OMIM 601,311).

## 2 | MATERIALS AND METHODS

### 2.1 | Subjects

The discovery sample consists of 101 unrelated Chinese adults, collected from more than 2000 random subjects in the form of extreme sampling, including 51 low hip BMD individuals ( $BMD < 0.785 \text{ g/cm}^2$ ) and 50 high hip BMD individuals ( $\text{Hip BMD} > 0.98 \text{ g/cm}^2$ ). All subjects were Han Chinese residents living in the vicinity of the central and western China, Changsha, and Xi'an, and their neighboring areas. All individuals with chronic diseases of vital organs, severe endocrine diseases, severe metabolic diseases, and severe nutritional diseases are not included in the research project. Individuals whose long-term medication may affect bone mass, bone structure, or metabolism or muscle development were not included in the study.

We replicated the pleiotropic single-nucleotide polymorphisms (SNPs) identified in the present study by the UKB cohort. In brief, the UKB cohort is a large prospective cohort study of ~500,000 participants from across the United Kingdom, aged between 40 and 69 at recruitment. Ethics approval for the UKB study was obtained from the North West Centre for Research Ethics Committee (11/NW/0382), and informed consent was obtained from all participants. This study used the data requested under the UKB application number 41,542, which was covered by the general ethical approval for the UKB study.

### 2.2 | Phenotype measurements and modeling

All subjects completed a structured questionnaire including lifestyle, medical history, family information, anthropometric variables, etc.

In the discovery sample, WLBM and fat body mass (FBM) were measured with a Hologic QDR 4,500 W DXA scanner (Hologic Inc.). Body weight was measured in light clothing on a calibrated balance beam scale. Height was obtained using a calibrated stadiometer. Covariates (including gender, age,  $\text{age}^2$ , height,  $\text{height}^2$ , FBM, and the first five principal components derived from genome-wide genotype data) were screened for significance with the step-wise linear regression model implemented in the SPSS software. The WLBM was adjusted through significant covariates, and the residuals were normalized by inverse quantiles of standard normal distribution.

In the replication sample, body composition was quantified by bioelectrical impedance approach. WLBM was approximated by the sum of fat-free mass at whole body. Phenotype modeling of WLBM was similar with that in the discovery samples. The difference is the phenotype in UKB was mandatorily adjusted by the top 10 principal components to adjust the potential population structure. Association was again examined by the linear regression model.

### 2.3 | Genotyping

In whole-exome sequencing (WES), the qualified genomic DNA subjects were randomly fragmented by ultrasonoscope (Covaris S2). The size of the library fragments is mainly distributed between 250 and 300 bp. Adapters were ligated to both ends of the resulting fragments. After extraction, we amplified DNA by ligation-mediated PCR (LM-PCR), purified, and hybridized to the NimbleGen 2.1M human exome array for enrichment. Non-hybridized fragments were then washed out. Both non-captured and captured LM-PCR products were subjected to quantitative PCR to estimate the magnitude of enrichment. Each captured library was then loaded onto HiSeq2000 platform. High-throughput sequencing was performed for each captured library to ensure that each subjects met the desired average sequencing depth (40× coverage). Raw image files were processed by Illumina base-calling software 1.7 for base-calling with default parameters. The sequences of each individual were generated as 90 bp pair-end reads. With the criteria that quality score of consensus genotype is at least 20, about 20 M reads passed the quality control (QC) in each subject.

Genome-wide genotypes for all subjects were available at 784,256 genotyped autosome markers, and were imputed into UK10K haplotype, 1,000 Genomes project phase 3, and Haplotype Reference Consortium (HRC) reference panels. All the included subjects are those who self-reported as white (data field 21,000). Subjects who had a self-reported gender inconsistent with the genetic gender, who were genotyped but not imputed, or who withdraw their consents were removed. A set of unrelated subjects were then sampled for subsequent analysis with KING (Manichaikul et al., 2010), based on the genome-wide genotyped variants.

### 2.4 | Genotype quality control

We followed strict genotype QC procedure at both individual and SNP levels. At the individual level, sex compatibility was checked by imputing sex from X-chromosome genotype data with PLINK (Purcell et al., 2007); individuals of unclear sex or of inconsistent with reported sex were removed. At the SNP level, the SNP that violates the Hardy–Weinberg equilibrium

( $p$  value  $< 1.0 \times 10^{-5}$ ) was removed. At the same time, the SNP with the Mendel error is set to the missing value.

### 2.5 | Population stratification

To monitor and correct for potential population stratification effects, we adopted a principal component analysis (PCA)-based correction for the detection of the discovery sample. PCA was applied to each individual sample (Zhang, Li, Pei, Liu, & Deng, 2009), and no population outliers were observed.

### 2.6 | Meta-analysis

Fisher's method, also known as Fisher's combined probability test, is a technique for data fusion or "meta-analysis" (analysis of analyses). It was developed by and named for Ronald Fisher. Significant genes found in the discovery subjects were further replicated in the replication subjects. Fisher's method was then used to analyze two gene-based association signals jointly. Specifically, Fisher's method was statistically calculated as:

$$\chi^2_{(4)} = -2 (\ln(p_1) + (p_2))$$

where  $p_1$  and  $p_2$  refer to two gene-level  $p$ -values. Under the null hypothesis of no association, this statistic approximately follows the Chi-square distribution with 4 degrees of freedom. Note that, Fisher's method is always valid regardless of whether the directions of two effect sizes are consistent.

### 2.7 | Functional annotation

Functional annotation of the discovered SNPs was performed using the bioinformatics software HaploReg (Ward & Kellis, 2012). The HaploReg database provides functional information for non-coded SNPs with multiple functional areas. The functional categories include conservation sites, DNase hypersensitivity sites (DHS), transcription factor binding sites (TFBS), promoter sites, enhancer sites, and others. We annotated these significant SNPs and their neighbor SNPs with strong linkage disequilibrium (LD) pattern ( $r^2 > .8$ ).

To investigate the association between the identified SNP polymorphisms and the nearby gene expressions, we used the Genotype-Tissue Expression (GTEx) Portal project dataset (Lonsdale et al., 2013; Westra et al., 2013a) and the Westra et al.'s study (Westra et al., 2013a) to perform cis-eQTL analysis. The GTEx project collected and RNA-sequenced multiple human tissues (up to 11,614) from donors who were also densely genotyped, and analyzed associations between

SNPs and global RNA expression within individual tissues. We downloaded the summary results of skeletal muscle tissue from the GTEx website (V7) (<https://www.gtexportal.org/home/>). The Westra et al.'s study performed the largest expression quantitative trait locus (eQTL) meta-analysis so far reported in non-transformed peripheral blood samples of 5,311 individuals, with replication in 2,775 individuals (Westra et al., 2013b). We obtained cis-eQTL results from the research website (<http://www.genenetwork.nl/bloodqtlbrowser/>). Cis-regulation refers to a potential functional genomic variation within or near a gene that significantly affects gene expression of a particular gene.

For candidate genes, we annotated them by constructing gene interaction networks with STRING (Szklarczyk et al., 2015). STRING uses information based on gene co-expression, text-mining, and others, to construct gene interactive networks.

## 2.8 | Mouse model survey

We surveyed mouse knockout models to evaluate muscle-related phenotypic consequence of the identified candidate genes, including changes in LBM ( $p < .05$ ). We primarily

**TABLE 1** Basic characteristics of the study subjects

	Discovery sample (101 Chinese)	
	Male	Female
No. of subjects	50	51
Age	29.32 (3.56)	28.80 (4.70)
Height (cm)	168.31 (5.38)	158.16 (5.89)
Weight (kg)	62.18 (9.78)	52.74 (7.54)
Fat body mass (kg)	16.10(5.20)	26.94(5.37)
Lean body mass (kg)	51.26 (6.96)	38.03 (4.79)

searched the International Mouse Phenotyping Consortium (IMPC) database via its web portal (<http://www.mousephenotype.org/>) (Dickinson et al., 2016).

## 3 | RESULTS


The basic characteristics of the subjects used in discovery sample are summarized in Table 1.

WES generates 332,246 SNPs that are included in the SNP-based association test in the discovery samples. The Bonferroni correction is used to declare the genome-wide significance level (GWS,  $0.05/332,246 = 1.5 \times 10^{-7}$ ). No SNPs achieved GWS. The most significant SNP is rs740681 ( $p = 1.66 \times 10^{-6}$ ). rs740681 is at 19p13.3; previous studies have reported that 19p13.3 was associated with LBM rs7249081 ( $2 \times 10^{-14}$ ) and rs546547223 ( $5 \times 10^{-6}$ ) (Hübel et al., 2019; Tachmazidou et al., 2017).

After adjusting phenotypes by PCA in each individual study, the genomic control inflation factor of the meta-analysis was 1.142, implying limited effect of potential population stratification. A logarithmic quantile–quantile (QQ) plot of the adjusted test statistics shows a marked deviation in the tail of the distribution, implying the possible existence of true associations (Figure 1).

We replicated the suggestive SNPs ( $p < 1.0 \times 10^{-3}$ ) in the UKB sample. Four SNPs were significant ( $p \leq .05$ ) in the UKB sample (Table 2). The effect direction at the SNP is consistent with that in the discovery stage for phenotypes. The main association results of the consistent SNP are listed in Table 2.

rs740681 is located in the *FZRI* (discovery  $p = 1.66 \times 10^{-6}$ , replication  $p = .05$ ), rs2272303, rs11170413, and rs2272302 are located in the *SOAT2* (discovery  $p = 3.99 \times 10^{-4}$ ,  $2.90 \times 10^{-4}$ , and  $9.13 \times 10^{-4}$ , respectively; replication  $p = 3.10 \times 10^{-4}$ ,  $2.90 \times 10^{-4}$ , and  $3.10 \times 10^{-4}$ , respectively).



**FIGURE 1** QQ plot. Logarithmic quantile–quantile (QQ) plot of the discovery sample

**TABLE 2** Significant association results for SNPs

SNP	Chr	Pos	Band	EA/OA	Gene	Discovery (N up to 101)			Replication (N up to 217,822)			<i>P</i> <sub>combined</sub>
						Beta	SE	<i>P</i>	Beta	SE	<i>P</i>	
rs740681	19	3,533,276	19p13.3	G/A	<i>FZRI</i>	4,220	819.3	$1.66 \times 10^{-6}$	0.00435	0.000224	0.05	$1.24 \times 10^{-5}$
rs2272303	12	53,105,721	12q13.13	A/G	<i>SOAT2</i>	-5514	1,412	$3.20 \times 10^{-4}$	-0.0096	0.0027	$3.10 \times 10^{-4}$	$1.46 \times 10^{-5}$
rs11170413	12	53,105,750	12q13.13	A/G	<i>SOAT2</i>	-5476	1,430	$3.99 \times 10^{-4}$	-0.0097	0.0027	$2.90 \times 10^{-4}$	$1.67 \times 10^{-5}$
rs2272302	12	53,105,703	12q13.13	C/G	<i>SOAT2</i>	-4933	1,387	$9.13 \times 10^{-4}$	-0.0096	0.0027	$3.10 \times 10^{-4}$	$3.67 \times 10^{-5}$

Notes: *FZRI*: X58380.1 (GenBank).

*SOAT2*: X51352.1 (GenBank).

Abbreviations: Beta, regression coefficient; Chr, chromosome; EA/OA, effect allele/non-effect allele; Pos, position; SE, standard error of Beta.

Meta-analysis *p*-values are ranging from  $1.24 \times 10^{-5}$  to  $3.67 \times 10^{-5}$ .

Manhattan plot of the discovery cohort is displayed in Figure 2. Regional plot of the genes *FZRI* and *SOAT2* are drawn by LocusZoom (Figure 3a,b, respectively).

### 3.1 | Functional annotation

We annotated each of the four replicated SNPs and their neighbor SNPs (LD  $r^2 \geq 0.8$ ) with HaploReg. rs740681 is an intron INDEL variant in *FZRI*. It has no neighbor variant with strong LD structure. rs2272303, rs11170413, and rs2272302 are mapping to a loci: 12q13.13. The leading SNP rs1117041 has 11 SNPs in strong LD pattern, and one SNP rs2272296 has the enhancer activity marked by H3K4me1 histone mark in skeletal muscle myoblast cells, which is also significant at the discovery stage ( $p = 1.83 \times 10^{-3}$ ).

From the skeletal muscle tissue summary results downloaded from the GTEx website (V7), we found that rs740681 shows an eQTL signal with *DOHH* in skeletal muscle ( $p = 1.80 \times 10^{-14}$ , Figure 4a). rs1170413, rs2272303, and rs2272302 show a cis-eQTL signal with *SOAT2* in Muscle-Skeletal ( $p = 1.50 \times 10^{-5}$ , Figure 4b-d).

In the study of peripheral blood by Westra et al, rs2272302 shows a cis-eQTL signal with gene *ITGB7* ( $p = 1.22 \times 10^{-17}$ ).

Gene-gene interaction network analysis of *FZRI* connected them to muscle-related genes such as *MYOD1*, *MYOG*, and so on (Figure 5).


Two genes have DXA scan results in the IMPC database. Heterozygous *FZRI*-deficiency mice have increased bone mineral content ( $p = .01$ ).

## 4 | DISCUSSION


In this study, we have performed WES study in 101 unrelated Chinese samples and replicated in two GWAS analyses. Combining the evidence from both the discovery and the replication samples, we have identified novel sarcopenia risk genes.

Previous studies implicate the ubiquitin-proteasome system (UPS) in myogenic differentiation through regulating cell cycle progression and modulating myogenic factors such as *MYOD* and *MYF5* (Li, Wu, & Wan, 2007). Certain ubiquitin protein ligases regulate muscle differentiation, such as *SKP1-CUL1-F-box* protein (*SCF*) and anaphase-promoting complex (*APC*), which have been suggested to govern terminal muscle differentiation. *SCF* have been suggested to govern *MYOD* protein degradation, while *APC* has been suggested to control *MYF5* proteolysis during the lineage of muscle differentiation (Gardrat, Montel, Raymond, &


**FIGURE 2** Manhattan plot of the discovery sample



**(a)**





**(b)**



**FIGURE 3** Regional plots. Regional plots of the discovery samples around genes *FZR1* (a) and *SOAT2* (b) are presented

**FIGURE 4** Represents an expression quantitative trait locus (eQTL) for seven significant SNPs expression in Muscle-Skeletal from the GTEx eQTL Browser. The Y-axis is the rank-normalized gene expression. rs740681 shows an eQTL signal with *DOHH* in Muscle-Skeletal ( $p = 1.80 \times 10^{-14}$ , (a)). rs1170413, rs2272303, and rs2272302 show a cis-eQTL signal with *SOAT2* in Muscle-Skeletal ( $p = 1.50 \times 10^{-5}$ , (b) (c) (d))



**FIGURE 5** Protein-protein interactions (PPI) network of *FZRI* connected them to muscle-related genes such as *MYOD1*, *MYOG*, and so on. Proteins in the interaction network were represented with nodes, while the interaction between any two proteins therein was represented with an edge. Line color indicates the type of interaction evidence including known interactions, predicted interactions, and other. These interactions contain direct (physical) and indirect (functional) interactions, derived from numerous sources such as experimental repositories and computational prediction methods. The figure was plotted by STRING

Azanza, 1997; Lindon, Albagli, Domeyne, Montarras, & Pinset, 2000; Tintignac et al., 2005).

*FZRI* (fizzy and cell division cycle 20 related 1) is a substrate-specific adapter for the anaphase promotion

complex/cyclosome (*APC/C*) *E3* ubiquitin-protein ligase complex and activation of *APC/C* in anaphase and late stage. The *APC/C* remains active in degrading substrates to ensure that positive regulators of the cell cycle

do not accumulate prematurely. *FZRI* and *CDHI* (cadherin 1) share the *CDHI* symbol. *CDHI* is sometimes used as an abbreviation for “CDC20 homolog 1”, which is an alternate name for the *FZRI*. *CDHI* is expressed in skeletal muscle cells (Gieffers, Peters, Kramer, Dotti, & Peters, 1999; Wan & Kirschner, 2001; Yoshiyuki, Judith, Takahiko, Shirin, & Azad, 2004). Results suggest that multiple *CDHI* may temporally and spatially regulate *APC* activity both within and outside of the cell cycle. *CDHI* may affect muscle cells (Wenqi, George, & Yong, 2007). *CDHI-APC* is an important ubiquitin *E3* ligase that regulates muscle differentiation by coordinating cell cycle progression and initiating a myogenic differentiation program.

*SOAT2* (sterol O-acyltransferase 2) is a member of a small family of acyl coenzyme A: cholesterol acyltransferases. The gene encodes a membrane-bound enzyme localized in the endoplasmic reticulum that produces intracellular cholesterol esters from long-chain fatty acyl *COA* and cholesterol. The cholesterol esters are then stored as cytoplasmic lipid droplets inside the cell. Several alternatively spliced transcript variants of this gene have been described, but their full-length nature is not known. It biased expression in small intestine (RPKM 4.5), duodenum. The gene has been found to be a major regulator of cholesterol metabolism and absorption factor Buhman et al., 2000). Impaired absorption of cholesterol is associated with high body mass index (BMI) and obesity (Miettinen & Gylling, 2000; Simonen, Gylling, Howard, & Miettinen, 2000).

**Conclusion:** By performing WES, we identified novel sarcopenia risk variants that may play roles in skeletal muscle metabolism. Our findings may provide useful information for understanding the mechanisms of sarcopenia.

## ACKNOWLEDGMENTS

We appreciate all the volunteers who participated in this study.

## CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

## AUTHOR CONTRIBUTIONS

Conceived and designed the experiments: H.W.D. and J.Y.W. Performed the experiments: S.R., L.Z., and X.H. Analyzed the data: L.Z., X.H., Z.X.J., Y.X.Z., Y.L., G.S.G Q.T., and Y.H.Z. Literature search: X.H., Y.X.Z., B.L.L, and Y.L., Wrote the paper: S.R., X.H., J.Y.W., and H.W.D. All authors reviewed and approved the manuscript.

## ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The study was approved by the Institutional Review Boards of Creighton University, University of Missouri-Kansas

City. Before entering the study, signed informed consent documents were obtained from all the participants.

## CONSENT FOR PUBLICATION

No applicable.

## DATA AVAILABILITY STATEMENT

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

## ORCID

Shu Ran  <https://orcid.org/0000-0002-6208-660X>

Xiao He  <https://orcid.org/0000-0002-7236-1572>

Zi-Xuan Jiang  <https://orcid.org/0000-0002-5291-6286>

Yu Liu  <https://orcid.org/0000-0003-2146-6865>

Yu-Xue Zhang  <https://orcid.org/0000-0001-5053-6100>

Jing-Yu Wang  <https://orcid.org/0000-0002-0130-4343>

Hong-Wen Deng  <https://orcid.org/0000-0002-7782-2956>

## REFERENCES

- Arden, N. K., & Spector, T. D. (2010). Genetic influences on muscle strength, lean body mass, and bone mineral density: A twin study. *Journal of Bone & Mineral Research the Official Journal of the American Society for Bone & Mineral Research*, 12(12), 2076–2081.
- Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R. et al (1998). Epidemiology of sarcopenia among the elderly in New Mexico. *American Journal of Epidemiology*, 147(8), 755–763. <https://doi.org/10.1093/oxfordjournals.aje.a009520>
- Brzeszczyńska, J., Meyer, A., Mcgregor, R., Schilb, A., Degen, S., & Tadani, V. et al (2017). Alterations in the in vitro and in vivo regulation of muscle regeneration in healthy ageing and the influence of sarcopenia. *J Cachexia Sarcopenia Muscle*, 9(1), 93–105. <https://doi.org/10.1002/jcsm.12252>
- Buckwalter, J. A. (1995). Osteoarthritis and articular cartilage use, disuse, and abuse: Experimental studies. *Journal of Rheumatology Supplement*, 43(43), 13–15.
- Buhman, K. K., Accad, M., Novak, S., Choi, R. S., Wong, J. S., Hamilton, R. L., ... Farese, R. V. (2000). Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice. *Nature Medicine*, 6(12), 1341–1347. <https://doi.org/10.1038/82153>
- Cauley, J. A. (2015). An overview of sarcopenic obesity. *Journal of Clinical Densitometry*, 18(4), 499–505. <https://doi.org/10.1016/j.jocd.2015.04.013>
- Cederholm, T., & Morley, J. E. (2015). Sarcopenia: The new definitions. *Current Opinion in Clinical Nutrition and Metabolic Care*, 18(1), 1–4. <https://doi.org/10.1097/MCO.0000000000000119>
- Chen, L. K., Liu, L. K., Woo, J., Assantachai, P., Auyeung, T. W., Bahyah, K. S. et al (2014). Sarcopenia in Asia: Consensus report of the Asian Working Group for Sarcopenia. *Journal of the American Medical Directors Association*, 15(2), 95–101. <https://doi.org/10.1016/j.jamda.2013.11.025>
- Dickinson, M. E., Flenniken, A. M., Ji, X., Teboul, L., Wong, M. D., White, J. K. et al (2016). High-throughput discovery of novel



- developmental phenotypes. *Nature*, 537(7621), 508–514. <https://doi.org/10.1038/nature19356>
- Fielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B. et al (2011). Sarcopenia: An undiagnosed condition in older adults. current consensus definition: Prevalence, etiology, and consequences. international working group on sarcopenia. *Journal of the American Medical Directors Association*, 12(4), 249–256. <https://doi.org/10.1016/j.jamda.2011.01.003>
- Gardrat, F., Montel, V., Raymond, J., & Azanza, J. L. (1997). Proteasome and myogenesis. *Molecular Biology Reports*, 24(1–2), 77.
- Gieffers, C., Peters, B. H., Kramer, E. R., Dotti, C. G., & Peters, J. M. (1999). Expression of the CDH1-associated form of the anaphase-promoting complex in postmitotic neurons. *Proceedings of the National Academy of Sciences of the United States of America*, 96(20), 11317–11322. <https://doi.org/10.1073/pnas.96.20.11317>
- Hayashi, M., Abe, K., Fujita, M., Okai, K., & Ohira, H. (2018). Association between sarcopenia and osteoporosis in chronic liver disease. *Hepatology Research*, 48(11), 893–904. <https://doi.org/10.1111/hepr.13192>
- Hsu, F. C., Lenchik, L., Nicklas, B. J., Lohman, K., Register, T. C., Mychaleckyj, J. et al (2012). Heritability of body composition measured by DXA in the diabetes heart study. *Obesity Research*, 13(2), 312–319. <https://doi.org/10.1038/oby.2005.42>
- Hübel, C., Gaspar, H. A., Coleman, J. R., Finucane, H., Purves, K. L., Hanscombe, K. B. et al (2019). Genomics of body fat percentage may contribute to sex bias in anorexia nervosa. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, 180(6), 428–438. <https://doi.org/10.1002/ajmg.b.32709>
- Joglekar, S., Nau, P. N., & Mezhir, J. J. (2015). The impact of sarcopenia on survival and complications in surgical oncology: A review of the current literature—Author response. *Journal of Surgical Oncology*, 112(5):503–509. <https://doi.org/10.1002/jso.24025>
- Li, W., Wu, G., & Wan, Y. (2007). The dual effects of Cdh1/APC in myogenesis. *The FASEB Journal*, 21(13), 3606–3617. <https://doi.org/10.1096/fj.07-8159com>
- Lindon, C., Albagli, O., Domeyne, P., Montarras, D., & Pinset, C. (2000). Constitutive instability of muscle regulatory factor Myf5 is distinct from its mitosis-specific disappearance, which requires a D-box-like motif overlapping the basic domain. *Molecular & Cellular Biology*, 20(23), 8923. <https://doi.org/10.1128/MCB.20.23.8923-8932.2000>
- Lonsdale, J., Thomas, J., Salvatore, M., Phillips, R., Lo, E., Shad, S. et al (2013). The Genotype-Tissue Expression (GTEx) project. *Nature Genetics*, 45, 580. <https://doi.org/10.1038/ng.2653>
- Manichaikul, A., Mychaleckyj, J. C., Rich, S. S., Daly, K., Sale, M., & Chen, W.-M. (2010). Robust relationship inference in genome-wide association studies. *Bioinformatics*, 26(22), 2867–2873. <https://doi.org/10.1093/bioinformatics/btq559>
- Miettinen, T. A., & Gylling, H. (2000). Cholesterol absorption efficiency and sterol metabolism in obesity. *Atherosclerosis*, 153(1), 241–248. [https://doi.org/10.1016/S0021-9150\(00\)00404-4](https://doi.org/10.1016/S0021-9150(00)00404-4)
- Monaco, M. D., Castiglioni, C., Monaco, R. D., & Tappero, R. (2017). Association between low lean mass and low bone mineral density in 653 women with hip fracture: Does the definition of low lean mass matter? *Aging Clinical & Experimental Research*, 29(6), 1–6. <https://doi.org/10.1007/s40520-017-0724-9>
- Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A., Bender, D. et al (2007). PLINK: A tool set for whole-genome association and population-based linkage analyses. *The American Journal of Human Genetics*, 81(3), 559–575. <https://doi.org/10.1086/519795>
- Roubenoff, R. (2000). Sarcopenic obesity: Does muscle loss cause fat gain?: Lessons from rheumatoid arthritis and osteoarthritis. *Annals of the New York Academy of Sciences*, 904(1), 553–557. <https://doi.org/10.1111/j.1749-6632.2000.tb06515.x>
- Simonen, P., Gylling, H., Howard, A. N., & Miettinen, T. A. (2000). Introducing a new component of the metabolic syndrome: Low cholesterol absorption. *American Journal of Clinical Nutrition*, 72(1), 82. <https://doi.org/10.1093/ajcn/72.1.82>
- Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., ... von Mering, C. (2015). STRING v10: Protein–protein interaction networks, integrated over the tree of life. *Nucleic Acids Research*, 43(D1), D447–D452. <https://doi.org/10.1093/nar/gku1003>
- Tachmazidou, I., Süveges, D., Min, J. L., Ritchie, G. R., Steinberg, J., Walter, K. et al (2017). Whole-genome sequencing coupled to imputation discovers genetic signals for anthropometric traits. *The American Journal of Human Genetics*, 100(6), 865–884. <https://doi.org/10.1016/j.ajhg.2017.04.014>
- Thomis, M. A. I., Huygens, W., Heuninckx, S., Chagnon, M., Maes, H. H. M., Claessens, A. L. et al (2004). Exploration of myostatin polymorphisms and the angiotensin-converting enzyme insertion/deletion genotype in responses of human muscle to strength training. *European Journal of Applied Physiology*, 92(3), 267–274. <https://doi.org/10.1007/s00421-004-1093-6>
- Tintignac, L. A., Julie, L., Sabrina, B., Valentina, S., Marie Pierre, L., & Leibovitch, S. A. (2005). Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. *Journal of Biological Chemistry*, 280(4), 2847–2856. <https://doi.org/10.1074/jbc.M411346200>
- Valter, S., Andrea, B., Massimiliano, M., & Marco, P. (2014). Clinical definition of sarcopenia. *Clinical Cases in Mineral and Bone Metabolism*, 11(3), 177–180.
- Vandewoude, M. F., Alish, C. J., Sauer, A. C., & Hegazi, R. A. (2012). Malnutrition-sarcopenia syndrome: Is this the future of nutrition screening and assessment for older adults? *Journal of Aging Research*, 2012, 1–8. <https://doi.org/10.1155/2012/651570>
- Wan, Y., & Kirschner, M. W. (2001). Identification of multiple CDH1 homologues in vertebrates conferring different substrate specificities. *Proceedings of the National Academy of Sciences of the United States of America*, 98(23), 13066–13071. <https://doi.org/10.1073/pnas.231487598>
- Ward, L. D., & Kellis, M. (2012). HaploReg: A resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Research*, 40(D1), D930–D934. <https://doi.org/10.1093/nar/gkr917>
- Wenqi, L., George, W., & Yong, W. (2007). The dual effects of Cdh1/APC in myogenesis. *The FASEB Journal*, 21(13), 3606–3617. <https://doi.org/10.1096/fj.07-8159com>
- Westra, H. J., Peters, M. J., Esko, T., Yaghootkar, H., Schurmann, C., & Kettunen, J. et al (2013). Systematic identification of trans eQTLs as putative drivers of known disease associations. *Nature Genetics*, 45(10), 1238–U195. <https://doi.org/10.1038/ng.2756>
- Westra, H. J., Peters, M. J., Esko, T., Yaghootkar, H., Schurmann, C., Kettunen, J. et al (2013). Systematic identification of trans-eQTLs as putative drivers of known disease associations. *Nature Genetics*, 45(10), 1238–U195. <https://doi.org/10.1038/ng.2756>
- Wolfe, R. R. (2006). The underappreciated role of muscle in health and disease. *American Journal of Clinical Nutrition*, 84(3), 475. <https://doi.org/10.1093/ajcn/84.3.475>
- Yoshiyuki, K., Judith, S., Takahiko, M., Shirin, B., & Azad, B. (2004). Cdh1-APC controls axonal growth and patterning in the mammalian brain. *Science*, 303(5660), 1026–30. <https://doi.org/10.1126/science.1093712>

- Zembroń-Łacny, A., Dziubek, W., Rogowski, Ł., Skorupka, E., & Dąbrowska, G. (2014) Sarcopenia: Monitoring, molecular mechanisms, and physical intervention. *Physiological Research*, 63(6),683.
- Zhang, L., Li, J., Pei, Y. F., Liu, Y., & Deng, H. W. (2009). Tests of association for quantitative traits in nuclear families using principal components to correct for population stratification. *Annals of Human Genetics*, 73(Pt 6), 601–13. <https://doi.org/10.1111/j.1469-1809.2009.00539.x>

**How to cite this article:** Ran S, He X, Jiang Z-X, et al. Whole-exome sequencing and genome-wide association studies identify novel sarcopenia risk genes in Han Chinese. *Mol Genet Genomic Med*. 2020;8:e1267. <https://doi.org/10.1002/mgg3.1267>